Business Wire

Digitate Accelerates Momentum as an Industry Leader in the AIOps Market

27.10.2021 16:00:00 EEST | Business Wire | Press release

Share

Digitate, a SaaS-based, leading provider of autonomous enterprise solutions, today announced its recognition as a market and category leader in AIOps by multiple leading analyst firms and industry reports. Digitate earned these merits as a result of its high customer ratings and wide breadth of solutions that span across IT and business operations, as well as assurance.

Digitate’s flagship product ignio™ is an end-to-end autonomous solution that uses advanced machine learning and AI capabilities to bring contextual intelligence to IT operations. ignio™ enables enterprises with a one-of-a-kind closed-loop solution that combines context, insights and intelligent automation to autonomously predict, prevent and prescribe for issues. Digitate is helping Fortune 500 companies harness the power of AI and automation as they scale to meet the demands of their own customers and ease the ever-increasing workload on IT teams.

"Our growth over the past few years speaks to the strength of our solutions in supporting our customers' goals for digital transformation success,” said Akhilesh Tripathi, CEO of Digitate. “Digitate is committed to providing customers an AI-driven, closed-loop platform that further improves productivity, business continuity, and customer experience. Our recognition as a market leader by several prominent analyst and industry reports is a validation of our investments and the adoption of our solutions across some of the world’s leading enterprises”

Digitate’s success is highlighted by several notable achievements and recognition in 2021, including:

  • Named a leader in the Omdia “AIOps Universe – Selecting an AIOps Solution 2021 - 2022” Report Due in part to its strong automation capabilities and management control, Digitate was recognized for its commitment to creating value for business functions through automation and comprehensive AIOps capabilities. Digitate was the leader in the overall customer experience with a recommendation score of 96%. To support Digitate’s all-rounder status, it scored 95% for solution breadth.
  • Recognized on the Constellation Research ShortList™ for Using Artificial Intelligence in IT Operations (AIOps) Q3 2021 – Constellation’s list evaluated over 40 most prominent AIOps solutions based on client inquiries, partner conversations, customer references, vendor selection projects, market share and internal research. Digitate was selected based on its noise reduction and enterprise capabilities, among other criteria.
  • Recognized as a technology leader in Quadrant Knowledge Solution’s SPARKS Matrix for Artificial Intelligence for IT Operations (AIOps) Platform 2021 Report –The report pointed out some of the key differentiators that include Digitate’s over 10 000 out-of-the-box automation capabilities and unique, closed-loop system ensuring better ROI and lower time to value.
  • Highlighted in the IDC Worldwide IT Operations Analytics Software Market Shares Report Digitate was the second fastest-growing IT Operations Analytics software company for 2020, with a revenue growth rate of 43.5%. (August 2021, IDC #US48125121)
  • Highlighted in the IDC Worldwide Workload Management Software Market Shares Report Digitate was the fastest growing WLM software company for 2020 with a revenue growth rate of 75.6 %. (July 2021, IDC #US48063321)

About Digitate

Digitate is a leading software provider bringing agility, assurance, and resiliency to IT and business operations. Digitate’s flagship product ignio™ is an award-winning AIOps software that reimagines enterprise IT and business landscape with its unique and innovative closed-loop approach by combining context, insights and intelligent automation to autonomously resolve and prevent issues. Our customers span across industry verticals and include large, global enterprises that are leaders and innovators in their respective industries. Digitate is headquartered in Santa Clara, California, USA and Pune, India. To stay up to date on ignio™ news and to learn more how our clients across the globe have benefited from our innovative solutions: Visit us at www.digitate.com, and follow Digitate on Twitter and LinkedIn.

Learn more about our AIOps solution here: http://www.youtube.com/watch?v=xy3FGkbZNDM

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Colin Rinehart
Senior Account Executive
10Fold/Digitate
digitate@10fold.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Restylane ® Contour™ for the Correction of Temple Hollowing23.3.2026 08:00:00 EET | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the U.S. FDA has approved Restylane Contour for the correction of temple hollowing in patients over the age of 21.1,2 This builds on its previous approvals for cheek augmentation and midface contour deficiencies, helping injectors address volume loss across key structural areas.1-3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260322108467/en/ With the broadest Injectable Aesthetics portfolio in the industry, this follows the recent U.S. approval of Restylane Lyft for augmentation of the chin region, adding to its indications to treat the midface, facial folds and wrinkles, back of hands, and the chin.4,5 Together, these approvals demonstrate Galderma’s ongoing commitment to evolving the versatile Restylane portfolio to deliver personalized, natural-looking outcomes that meet diverse patient needs.1,4,6,7 The volume of the temples can dimi

Paving the Way for Real‑Time Earth Observation: Space Compass and SWISSto12 Sign Contract for First Commercial GEO Optical Data Relay Satellite23.3.2026 06:00:00 EET | Press release

Space Compass Corporation (“Space Compass”) and SWISSto12 SA (“SWISSto12”) announced today that they have executed a procurement contract for the first GEO optical data relay satellite. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320584108/en/ (From Left to Right): Julie Pignon, Legal Counsel, SWISSto12; 倉田 るり子 (Ruriko Kurata), Legal Counsel, Space Compass; 小松 大実 (Hiromi Komatsu), Co-CEO, Space Compass; 田中 良太 (Ryota Tanaka), Engineering Director, Space Compass; Emile de Rijk, CEO, SWISSto12; Fredrik Gustavsson, Chief Financial and Strategy Officer, SWISSto12. This agreement represents a major milestone toward the realization of Space Compass’s optical data relay service. With high-speed, high-capacity optical data relay service, Space Compass aims to transform Earth Observation from just a tracking record into a real-time decision-making tool. For SWISSto12, the contract represents further validation of the company’s a

Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting20.3.2026 16:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that data from key programs in its Inflammation and Autoimmunity (IAI) franchise will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, to be held March 27 – 31, 2026, in Denver. “At AAD 2026, we are presenting late‑breaking 54-week results from the Phase 3 STOP‑HS program evaluating povorcitinib in hidradenitis suppurativa (HS),” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation and Autoimmunity, Incyte. “These data provide longer term evidence of the safety and efficacy of povorcitinib in HS patients and further strengthen the significant growth potential of our Inflammation and Autoimmunity franchise.” Details on key data presentations at AAD include: Late-Breaking Oral Presentations Hidradenitis Suppurativa Povorcitinib in Patients With Moderate to Severe Hidradenitis Suppurativa: 54-Week Efficacy and Safety Results From the STOP-HS1 & STOP-HS2 Phase 3 Studies (Session: S034 – Late-Breaking Research: Sess

MUSASHI JAPAN by TAIMATSU Launches “Road to Shogun” – A Journey Through Craftsmanship and Discovery20.3.2026 14:58:00 EET | Press release

Musashi Japan by TAIMATSU Co., Ltd., a contemporary Japanese knife brand rooted in the spirit of craftsmanship and cultural harmony, has announced its newest experiential campaign: “Road to Shogun.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320887471/en/ Designed as the brand’s most ambitious customer journey to date, the campaign invites visitors to explore participating Musashi Japan stores while discovering the traditions, culture and craftsmanship that inspire the brand. Inspired by the journey towards mastery, the experience encourages participants to progress through a series of ranks whilst visiting stores and unlocking rewards that celebrate elements of everyday Japanese culture. At Musashi Japan, craftsmanship is not only about the final product, but also about the path taken to achieve mastery. The Road to Shogun reflects this philosophy by guiding customers through a journey that mirrors the dedication, cu

Futur Delivers Strong Growth and Record Profit in 202520.3.2026 13:05:00 EET | Press release

"2025 was a record year for Futur. In a market characterized by sharp market fluctuations, Futur continued to invest, grow and deliver strong results. Behind this record performance is stable customer growth, strong inflows and cost discipline. Our close cooperation with over 60 partners gives customers the freedom to choose the asset management and advisory services that best suit them. The strategy of letting the customer choose is appreciated, which is reflected in us welcoming more than 21,000 new customers during the year", says Torgny Johansson, CEO of Futur. "We are optimistic about the future. Futur has great opportunities to continue growing in the coming years by developing innovative and efficient services for savings and pensions. I am proud of how all employees have purposefully embraced our strategy and continue to work towards the goal of reaching 500 billion kronor in savings capital with the current organization", concludes Torgny Johansson, CEO of Futur. Key highlight

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye